Lightpoint medical is a growth-stage and revenue generating medical device company founded in 2012 by Dr David Tuch, a highly experienced scientist specialising in medical imaging and pharmaceutical sectors.. Lightpoint was formed to address a widespread medical problem faced by cancer patients, namely, that cancer surgery is very often unsuccessful. Cancer surgery is frequently unsuccessful for the simple reason that surgeons cannot see cancer during surgery. Cancer surgeons are completely reliant on their sense of touch and naked eye. Lightpoint develops and markets medical imaging technologies that surgeons can use during surgery to find the cancer and improve the outcome of the surgery.
The company has four products under various stages of development: The LightPath® Imaging System (CE marked) for imaging surgical specimens and is in the early sales stage, the PICO™ laparoscopic probe for minimally-invasive prostate surgery (under development), HARLI™ for the life sciences market (launched), and Clovis (under development) for open surgery. The company’s products address the pressing medical need for better tools to detect cancer during surgery in order to improve clinical outcomes and reduce healthcare costs. Whilst the technology is applicable across a wider number of cancer types, Lightpoint Medical’s focus is on prostate and breast cancer surgery.
Lighpoint is now seeking investment of £5m in it’s series B funding round to further enhance product development, increase the number of sales and marketing distribution channels and to cover clinical expense.